Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...

CrowdStrike reiterated its long-term ambition, which continues to anchor the model: reaching $10 billion in subscription ARR by fiscal 2031. Framed against today's run rate, this target assumes the ...

Big Easy SEO announces the launch of a Maps SEO service focused on how businesses appear in Google’s local results and map interface. The announcement identifies Maps SEO as a defined addition to the ...

Kingspan shares soared on Tuesday as the insulation manufacturer said it is considering floating its advanced building ...

HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of ...

Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile ...

Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment ...

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI rema ...

JPMorgan U.S. All Stars Conference September 16, 2025 4:00 AM EDTCompany ParticipantsPaul Jacobson - Executive VP ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints.

Akeso Inc. (9926.HK) is excited to announce that the Late-Breaking Abstract (LBA) from the registrational Phase ...